These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 7903542)

  • 41. The diffusion of innovation in AIDS treatment: zidovudine use in two New Jersey cohorts.
    Crystal S; Sambamoorthi U; Merzel C
    Health Serv Res; 1995 Oct; 30(4):593-614. PubMed ID: 7591783
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Development and significance of zidovudine resistance in children infected with human immunodeficiency virus.
    Ogino MT; Dankner WM; Spector SA
    J Pediatr; 1993 Jul; 123(1):1-8. PubMed ID: 8100579
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Trend towards decreased survival in patients infected with HIV resistant to zidovudine.
    Gøtzsche PC; Nielsen C; Gerstoft J; Nielsen CM; Vestergaard BF
    Scand J Infect Dis; 1992; 24(5):563-5. PubMed ID: 1361240
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Early intervention in HIV infection: where are we?
    Collier AC
    AIDS Res Hum Retroviruses; 1994 Aug; 10(8):893-9. PubMed ID: 7811539
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of intravenous immunoglobulin (IVIG) on CD4+ lymphocyte decline in HIV-infected children in a clinical trial of IVIG infection prophylaxis. The National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group.
    Mofenson LM; Bethel J; Moye J; Flyer P; Nugent R
    J Acquir Immune Defic Syndr (1988); 1993 Oct; 6(10):1103-13. PubMed ID: 8105072
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical correlates of in vitro HIV-1 resistance ot zidovudine. Results of the Multicentre Canadian AZT Trial.
    Montaner JS; Singer J; Schechter MT; Raboud JM; Tsoukas C; O'Shaughnessy M; Ruedy J; Nagai K; Salomon H; Spira B
    AIDS; 1993 Feb; 7(2):189-96. PubMed ID: 8466681
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The role of HIV type 1 phenotype and genotype in long-term responders to zidovudine therapy.
    Angarano G; Monno L; Vivirito MC; Appice A; Romanelli C; Giannelli A; La Grasta L; Fracasso C; Fiore JR; Milazzo F
    AIDS Res Hum Retroviruses; 1996 Jul; 12(11):969-75. PubMed ID: 8827212
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Preliminary results in HIV-1-infected patients treated with transfer factor (TF) and zidovudine (ZDV).
    Raise E; Guerra L; Viza D; Pizza G; De Vinci C; Schiattone ML; Rocaccio L; Cicognani M; Gritti F
    Biotherapy; 1996; 9(1-3):49-54. PubMed ID: 8993757
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Are HIV-infected patients with rapid CD4 cell decline a subgroup who benefit from early antiretroviral therapy?
    Easterbrook PJ; Goodall RL; Babiker AG; Yu LM; Smith D; Cooper DA; Gazzard BG
    J Antimicrob Chemother; 1999 Mar; 43(3):379-88. PubMed ID: 10223594
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of antiretroviral therapy on the cerebrospinal fluid of patients seropositive for the human immunodeficiency virus.
    Gulevich SJ; McCutchan JA; Thal LJ; Kirson D; Durand D; Wallace M; Mehta P; Heyes MP; Grant I
    J Acquir Immune Defic Syndr (1988); 1993 Sep; 6(9):1002-7. PubMed ID: 8101873
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Population-based estimates of zidovudine and aerosol pentamidine use in San Francisco: 1987-1989.
    Lang W; Osmond D; Samuel M; Moss A; Schrager L; Winkelstein W
    J Acquir Immune Defic Syndr (1988); 1991; 4(7):713-6. PubMed ID: 1675679
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A follow-up study of neuropsychological functioning in AIDS-patients. Prognostic significance and effect of zidovudine therapy.
    Karlsen NR; Reinvang I; Frøland SS
    Acta Neurol Scand; 1995 Mar; 91(3):215-21. PubMed ID: 7793239
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of sex, age and transmission category on the progression to AIDS and survival of zidovudine-treated symptomatic patients.
    Vella S; Giuliano M; Floridia M; Chiesi A; Tomino C; Seeber A; Barcherini S; Bucciardini R; Mariotti S
    AIDS; 1995 Jan; 9(1):51-6. PubMed ID: 7893441
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prognostic factors in human immunodeficiency virus-positive patients with a CD4+ lymphocyte count < 50/microL.
    Apolonio EG; Hoover DR; He Y; Saah AJ; Lyter DW; Detels R; Kaslow RA; Phair JP
    J Infect Dis; 1995 Apr; 171(4):829-36. PubMed ID: 7706809
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Persistence of Macrocytosis after Discontinuation of Zidovudine in HIV-Infected Patients.
    Yu I; Greenberg RN; Crawford TN; Thornton AC; Myint T
    J Int Assoc Provid AIDS Care; 2017; 16(5):512-515. PubMed ID: 28393661
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of zidovudine in 30 patients with mild to end-stage AIDS dementia complex.
    Tozzi V; Narciso P; Galgani S; Sette P; Balestra P; Gerace C; Pau FM; Pigorini F; Volpini V; Camporiondo MP
    AIDS; 1993 May; 7(5):683-92. PubMed ID: 8318176
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Exposure to zidovudine adversely affects mitochondrial turnover in primary T cells.
    Wallace ZR; Sanderson S; Simon AK; Dorrell L
    Antiviral Res; 2016 Sep; 133():178-82. PubMed ID: 27496003
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Zidovudine-associated adverse reactions in a longitudinal study of asymptomatic HIV-1-infected homosexual males.
    Baum MK; Javier JJ; Mantero-Atienza E; Beach RS; Fletcher MA; Sauberlich HE; Feaster D; Shor-Posner G
    J Acquir Immune Defic Syndr (1988); 1991; 4(12):1218-26. PubMed ID: 1941528
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Endogenous interferon and triglyceride concentrations to assess response to zidovudine in AIDS and advanced AIDS-related complex.
    Mildvan D; Machado SG; Wilets I; Grossberg SE
    Lancet; 1992 Feb; 339(8791):453-6. PubMed ID: 1371323
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Long-term zidovudine reduces neurocognitive deficits in HIV-1 infection.
    Baldeweg T; Catalan J; Lovett E; Gruzelier J; Riccio M; Hawkins D
    AIDS; 1995 Jun; 9(6):589-96. PubMed ID: 7662198
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.